Clinical trials: Covid-19 Pneumonia
Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)
The study is a prospective, randomized, placebo-controlled, single-blind phase 2 clinical study of the efficacy and safety of AMY-101, a potent C3 inhibitor, for the management of patients with ARDS caused by SARS-CoV-2…
- Trial name
- SAVE (NCT04395456)
- Testing
- AMY-101, WFI 5% glucose
- Volunteers
- 144 people
- Sponsor
- Amyndas Pharmaceuticals S.A.
Covid-19, SARS-CoV 2
Baricitinib Compared to Standard Therapy in Patients With COVID-19
There is urgent need of an effective therapy for Covid-19. To date, the best treatment of SARS-CoV-2 infection is unknown. Baricitinib has been identified as potential treatment for 2019-nCoV acute respiratory disease, because of…
- Conditions
- Covid-19, SARS-CoV 2, SARS Pneumonia
- Trial name
- BARICIVID-19 (NCT04393051)
- Testing
- Baricitinib Oral Tablet
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
COVID-19, Surgery
Impact of COVID-19 Pandemic on Hepatopancreatobiliary Surgical Services in Singapore
This paper is intended to report our observational study in evaluating the impact of the COVID-19 pandemic on Tan Tock Seng Hospital hepatopancreatobiliary unit's surgical workload from January to June across 2019 to 2022…
- Trial name
- NCT05572866
- Testing
- COVID-19 pandemic
- Where
- Singapore
- Volunteers
- 1,089 people
- Sponsor
- Tan Tock Seng Hospital
COVID-19 Pneumonia
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
- Trial name
- NCT04561180
- Testing
- EG-009A, Standard of Care, Dexamethasone
- Sponsor
- Evergreen Therapeutics, Inc.
COVID-19, SARS-CoV-2 Infection
COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in specific subjects cohorts.
- Trial name
- NCT05096962
- Testing
- Quantitative analysis of SARS-CoV-2 antibodies, Cellular immunity
- Where
- Czechia
- Volunteers
- 7,268 people, healthy volunteers welcome
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic
Covid19, SARS-CoV2 Infection
Monitoring the Effectiveness and Safety of COVID-19 Vaccines at National University of Colombia
There are relevant questions that need to be answered about the effectiveness and safety of COVID-19 vaccines. The objective of this observational study is to follow up the clinical outcomes after vaccination in all the…
- Trial name
- NCT04887246
- Testing
- COVID-19 vaccines
- Where
- Colombia
- Volunteers
- 4,078 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Colombia
COVID-19 Respiratory Infection, COVID-19 Vaccine Adverse Reaction
A Randomized, Phase I Study of DNA Vaccine OC-007 as a Booster Dose of COVID-19 Vaccine
This is a randomized, placebo-controlled, double-blinded phase I study, designed to evaluate the safety including reactogenicity and immunogenicity of this investigational DNA vaccine delivered intramuscularly by in vivo EP in…
- Trial name
- OpenCorona1 (NCT05685953)
- Testing
- DNA vaccine OC-007
- Where
- Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Matti Sällberg
COVID 19
Comparison of Cardiopulmonary Fitness Level With Normal Values After COVID-19
COVID-19 (Coronavirus disease 2019) is a new infectious disease caused by a virus named as SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2).
- Trial name
- NCT04753346
- Testing
- Physical Activity Level, Anxiety and Depression Assessment, Exercise Capacity
- Where
- Turkey (Türkiye)
- Volunteers
- 240 people
- Sponsor
- Ankara University
Covid19
Immunohematology in COVID-19 Patients: A Hospital-based Retrospective Cohort Study
This is a hospital-based retrospective cohort study and the Immunohematologic characteristics of COVID-19 patients will be investigated systematically.
- Trial name
- NCT04932954
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- LI YAN
Covid19
Nervous System Symptoms Associated With COVID 19
This study aim to prospectively evaluate the neuropsychiatric symptoms of patients infected with the SARS-CoV-2 virus by a standardized neuropsychiatric examination : the global CASE scale (Clinical Assessment Scale in Autoimmune…
- Trial name
- NS-COV (NCT04922905)
- Testing
- NEURO +, NEURO -
- Where
- France
- Volunteers
- 99 people
- Sponsor
- University Hospital, Toulouse
SARS-CoV-2 Infection
Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection
The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test)…
- Trial name
- SCORPIO-PEP (NCT05897541)
- Testing
- S-217622
- Where
- 178 sites in United States, Argentina and 3 more
- Volunteers
- 3,701 people, healthy volunteers welcome
- Sponsor
- Shionogi
COVID-19 Pandemic
NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
This is a prospective, multicenter, randomized (3:1), placebo- controlled, parallel-group, double-blind trial. Patients will be randomized into two arms of treatment: Placebo + SoC (N=30) NanoManganese® + SoC (N=90) Patients will…
- Trial name
- NCT05451654
- Testing
- Experimental drug
- Where
- Brazil
- Volunteers
- 7 people
- Sponsor
- Medesis Pharma SA
Cancer, Covid19
CCP Cancer UK Companion Study
Currently, there is extremely limited information regarding the risks posed by SARS-CoV-2 to patients with cancer. This study aims to understand the presentation, management and outcomes of patients with cancer.
- Trial name
- NCT04603105
- Where
- United Kingdom
- Volunteers
- 9,000 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Myeloproliferative Disease, COVID - 19
Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study)
The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of JAK2, CALR or MPL genes.
- Trial name
- NCT07204366
- Where
- Italy
- Volunteers
- 219 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
COVID-19
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from…
- Trial name
- NCT04295551
- Testing
- Lopinavir / ritonavir tablets combined with Xiyanping injection, Lopinavir/ritonavir treatment
- Volunteers
- 80 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Acute Respiratory Distress Syndrome, COVID19 Infection
Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection
It is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study. Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours.
- Trial name
- SEVO-COVID19 (NCT04359862)
- Testing
- Sevoflurane, Propofol
- Where
- 5 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Immunodeficiency, Immunosuppression
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce…
- Conditions
- Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease
- Trial name
- NCT05655546
- Testing
- Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- Scripps Translational Science Institute
COVID-19
Colchicine Plus Phenolic Monoterpenes to Treat COVID-19
In this randomized controlled clinical trial, defined cases of COVID-19 with mild, moderate, or severe pneumonia (according to the NIH guideline) were treated with conventional treatment regimens (controls) as well as in…
- Trial name
- NCT04392141
- Testing
- Standard Treatment, Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions
- Where
- Iran
- Volunteers
- 120 people
- Sponsor
- Kermanshah University of Medical Sciences
COVID-19
Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19)
Objective: To assess the prognostic value of high-sensitive cardiac troponin T (hs-cTnT) and N-terminal pro brain natriuretic peptide (NT-proBNP) at ICU admission in patients with coronavirus disease 2019 (COVID-19).
- Trial name
- COROBIOCHIC (NCT04641988)
- Where
- France
- Volunteers
- 111 people
- Sponsor
- University Hospital, Montpellier
Mental Health Impairment
National Survey of Mental Health After COVID-19 Outbreak
The Serbian national survey - acronym CoV2Soul.RS - has been launched to document mental health (MH) status and understand needs of the population in relation to the prolonged global public health crisis.
- Trial name
- CoV2SoulRS (NCT04896983)
- Where
- 3 sites in Serbia
- Volunteers
- 1,200 people
- Sponsor
- University of Belgrade
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.